Pilot trial of alternating paclitaxel and doxorubicin in advanced breast cancer

Keyphrases

• Paclitaxel 100%
• Doxorubicin 100%
• Advanced Breast Cancer 100%
• Chemotherapy 33%
• Cardiac Toxicity 33%
• Objective Response 33%
• Adverse Effects 16%
• Adjuvant Therapy 16%
• No Significant Difference 16%
• Lymph Node 16%
• Metastatic Disease 16%
• Breast Cancer 16%
• Metastatic Breast Cancer 16%
• Complete Response 16%
• Thrombocytopenia 16%
• Left Ventricular Dysfunction 16%
• Partial Response 16%
• Duration of Response 16%
• Granulocytes 16%
• Metastasis Sites 16%
• Dose-limiting Toxicity 16%
• Arthralgia 16%
• Soft Tissue 16%
• Taxanes 16%
• Breast Cancer Recurrence 16%
• Intravenous Infusion 16%
• Prior Chemotherapy 16%
• Peripheral Neuropathy 16%
• Anthracyclines 16%
• Myalgia 16%
• Sinus Tachycardia 16%
• Two-agent 16%
• Sinus Bradycardia 16%
• T-wave Abnormality 16%
• Alternating Cycle 16%
• Alternating Regimen 16%

Medicine and Dentistry

• Breast Cancer 100%
• Doxorubicin 100%
• Paclitaxel 100%
• Metastatic Carcinoma 33%
• Cardiotoxicity 33%
• Chemotherapy 33%
• Adverse Event 16%
• Arthralgia 16%
• Adjuvant Therapy 16%
• Neuropathy 16%
• Thrombocytopenia 16%
• Heart Left Ventricle Failure 16%
• Lymph Node 16%
• Granulocyte 16%
• Allergic Response 16%
• Intravenous Drug Administration 16%
• T Wave 16%
• Patient History of Chemotherapy 16%
• Metastatic Breast Cancer 16%
• Myalgia 16%
• Anthracycline 16%
• Sinus Bradycardia 16%
• Sinus Tachycardia 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Breast Cancer 100%
• Doxorubicin 100%
• Paclitaxel 100%
• Chemotherapy 33%
• Cardiotoxicity 33%
• Arthralgia 16%
• Adverse Event 16%
• Thrombocytopenia 16%
• Heart Left Ventricle Failure 16%
• Metastasis 16%
• Allergic Reaction 16%
• Neuropathy 16%
• Metastatic Breast Cancer 16%
• Patient History of Chemotherapy 16%
• Anthracycline 16%
• Sinus Tachycardia 16%
• Myalgia 16%
• Sinus Bradycardia 16%
• Taxane 16%